title: Batanopride (BMY-25801): a new 5-HT3 receptor antagonist for the prevention of cancer chemotherapy-induced emesis.
authors: Bristol-Myers Squibb, Pharmaceutical Research Institute, Wallingford, CT 06492-7660.
authors: L
authors: L
authors: Smaldone
authors: P
authors: P
authors: Plezia
authors: D
authors: D
authors: Alberts
authors: M
authors: M
authors: Aapro
authors: G
authors: G
authors: Sartiano
authors: M
authors: M
authors: Dorn
authors: M
authors: M
authors: Brady
authors: C
authors: C
authors: Comerski
authors: S E
authors: SE
authors: Schwartz
authors: C
authors: C
authors: Fairchild
mesh_terms: D000818:Animals; D000932:Antiemetics / Q000493:pharmacokinetics / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects*; D002945:Cisplatin / Q000009:adverse effects; D004285:Dogs; D018492:Dopamine Antagonists; D005260:Female; D005289:Ferrets; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D008297:Male; D008787:Metoclopramide / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D051379:Mice; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy*; D051381:Rats; D012702:Serotonin Antagonists / Q000493:pharmacokinetics / Q000627:therapeutic use; D014839:Vomiting / Q000139:chemically induced / Q000517:prevention & control*
chemical_list: D000932:Antiemetics; D000970:Antineoplastic Agents; D018492:Dopamine Antagonists; D012702:Serotonin Antagonists; C060190:batanopride; D008787:Metoclopramide; D002945:Cisplatin